Taizhou Hanzhong biomedical co. LTD Report issue

Government Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03704246
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Taizhou Hanzhong biomedical co. LTD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Thyroid Carcinoma, Anaplastic (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 10